Physician profile
Amy M Riley
NPI 1528009552
$8,416.18
in general payments reported to CMS, 2019-2025
47 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,843 · 2022: $1,861 · 2023: $2,532 · 2024: $1,883 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,078 · Education: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,077.95 |
| Education | $634.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,401.65 | 2021-2024 | Opdivo, Eliquis, Augtyro |
| Incyte Corporation | $792.03 | 2021-2023 | Jakafi, Pemazyre, Monjuvi |
| Lilly USA, LLC | $588.82 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $536.95 | 2022-2024 | |
| Eisai INC. | $472.31 | 2021-2024 | |
| Beigene USA, INC. | $443.28 | 2021-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $359.77 | 2021-2024 | Ninlaro, Iclusig, Fruzaqla |
| Celgene Corporation | $323.87 | 2022-2023 | Reblozyl, Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $315.93 | 2021-2024 | Enhertu, Injectafer |
| Abbvie INC. | $303.99 | 2021-2025 | |
| Janssen Biotech, INC. | $287.10 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Seagen INC. | $258.52 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Exelixis INC. | $212.65 | 2021-2024 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $204.61 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $200.09 | 2021-2024 | Keytruda, Welireg, Reblozyl |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $177.07 | 2021-2024 | |
| Glaxosmithkline, LLC. | $162.02 | 2021-2023 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $125.63 | 2021-2024 | Lynparza, Enhertu, Calquence |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Astellas Pharma US INC | $112.60 | 2021-2024 | Xtandi |
| Genentech USA, INC. | $98.24 | 2022-2024 | Tecentriq, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $83.67 | 2022-2023 | Imbruvica |
| Amgen INC. | $74.95 | 2021-2023 | Kyprolis, Blincyto |
| Genzyme Corporation | $71.29 | 2021-2023 | |
| Celltrion USA INC. | $61.20 | 2024 | Vegzelma |
| Kite Pharma, INC. | $54.16 | 2021-2023 | Yescarta |
| Array Biopharma INC | $51.24 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Pharmaessentia USA Corporation | $50.97 | 2023-2024 | Besremi |
| Ipsen Biopharmaceuticals, INC | $41.42 | 2023 | Tazverik |
| Emd Serono, INC. | $38.21 | 2021-2023 | Tepmetko |
| Taiho Oncology, INC. | $36.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.13 | 2024 | Austedo Xr |
| Epizyme, INC. | $34.72 | 2021 | |
| Stemline Therapeutics INC. | $30.45 | 2024 | Orserdu |
| Pharmacosmos Therapeutics INC. | $23.61 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2021 | |
| Rigel Pharmaceuticals, INC. | $22.55 | 2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $21.17 | 2023 | |
| Morphosys, US INC. | $20.71 | 2023 | Monjuvi |
| Genmab U.S., INC. | $19.88 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.55 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.19 | 2021 | |
| Aveo Pharmaceuticals, INC. | $18.02 | 2024 | |
| Mirati Therapeutics, INC. | $17.21 | 2024 | Krazati |
| Acceleron Pharma, INC. | $17.14 | 2021 | |
| Coherus Oncology, INC. | $16.06 | 2023 | |
| Gilead Sciences, INC. | $13.99 | 2023 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.